

# Container Closure Integrity Evaluation for Sterile Product Packages

Jia Min, Boo, Technical Customer Support, West Pharmaceutical Services  
13<sup>th</sup> Oct 2020



# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - Materials
  - Measurements
  - Environments
- Summary

当承科技(上海)有限公司文献推荐

# Content

- **What is CCI?**
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - Materials
  - Measurements
  - Environments
- Summary

当承科技(上海)有限公司文献推荐

# Sterile Products

- A parenteral package must keep the product sterile.
- Sterile product is “free from viable microbial contamination throughout the product’s entire shelf life or dating period”

FDA Guidance for Industry,  
Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile  
Products, February 2008


# Terminology

- CCI IS THE SAME AS
  - Package integrity testing
  - Package leak testing
- CCI is NOT simply defined as microbial barrier protection
- CCI is NOT solely determined via microbial challenge tests

CCI is achieved when a package meets the  
**MAXIMUM ALLOWABLE LEAKAGE LIMIT**  
required to ensure product quality attributes of  
sterility and physicochemical stability through expiry

# Inherent Package Integrity

- The leakage rate of a **no-defect, well-assembled** package
  - Leakage occurs between mechanically fitted components
  - Leakage may occur between physiochemically bonded components
- **Leakage > inherent integrity leak** rate caused by
  - Poor assembly
  - Component defects



**Maximum allowable leakage limit (MALL)** is that ***smallest gap*** or ***leak rate*** that puts product quality at risk (called “critical leak”)

**INHERENT package integrity must be  $\leq$  MALL**

# Content


- What is CCI?
- **Importance of CCI**
- Regulations and Guidances
- CCI Understanding
  - Materials
  - Measurements
  - Environments
- Summary

当承科技(上海)有限公司文献推荐

# Particulates and lack of sterility cause most product recalls



## Reason For Injectable Product Recall



- Other Reason - Misc issues with the drug, delivery device, or labelling
- Potential Lack of Sterility - Including risk to container closure integrity
- Detected Foreign Particulate - Including glass, rubber, microbes, etc.



Regulatory agencies driving for better product quality

Referenced from U.S. FDA (2020). Recalls, Market Withdrawals, & Safety Alerts. Retrieved from <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts>.




# Importance of CCI

- CCI is one of the major concerns, leading to recalls and risk to patient safety.
- CCI testing is a growing concern for all packages because:
  - Packaging is becoming more complex
  - More CCI tests are being developed, but no one method works for all applications
  - Better understanding about CCI, e.g., CCI of lyo drug product and CCI at cold storage temperatures
  - Regulatory encouragement to use CCI test instead of sterility test

# Content

- What is CCI?
- Importance of CCI
- **Regulations and Guidances**
- CCI Understanding
  - Materials
  - Measurements
  - Environments
- Summary


# Regulations and Guidances



# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- **CCI Understanding**
  - Materials
  - Measurements
  - Environments
- Summary


# CCI Understanding



Referenced from Degrazio FL. 2018, 'Holistic Considerations in Optimizing a Sterile Product Package to Ensure Container Closure Integrity', *PDA J Pharm Sci Technol.*, vol. 72, no. 1, pp. 15-34.

# Process Flow for Selecting Packaging to Ensure CCI

- Each factor needs to be gauged together- not independently- to ensure an optimized package
- There's no industry best practice standard defined for qualifying an acceptable container closure system platform for CCI currently



Referenced from Degrazio FL. 2018, 'Holistic Considerations in Optimizing a Sterile Product Package to Ensure Container Closure Integrity', *PDA J Pharm Sci Technol.*, vol. 72, no. 1, pp. 15-34.

# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - **Materials**
  - Measurements
  - Environments
- Summary

当承科技(上海)有限公司文献推荐

# Materials

- Glass Vial Container
- Elastomeric Stopper
- Films/Coatings for Closures
- Fit among the Components




Typical Primary Parenteral Vial System




# Glass Vial Container


- Examples of quality defects that can affect the CCI of a vial system. Defects of either the stopper or the glass vial have the potential to affect integrity.



Fiber in the stopper



Crack on vial lip



Chipped lip of vial

# Elastomer Stopper

- Hardness of Elastomer
- Material Modulus
- Elastomer Viscoelasticity
- Component Surface Lubricity



Stopper Pop-up Following Lyophilization

Example of stopper pop-up phenomenon that can occur immediately after completion of the lyophilization process but before flip-off seals are used. The stopper pop-up can vary in amount; however, any stopper movement can cause a breach in integrity. Photo courtesy of Ed Trappier and Lyophilization Technology, Inc.

Stopper Insertion Problems Due to Lack of sufficient Lubricity




An example of a stopper that does not have enough surface lubrication. This leads to the stopper popping-up following insertion into a glass vial. Friction between the interface of the stopper and glass may affect machinability or other issues that indirectly lead to poor integrity. Photo courtesy of West Pharmaceutical Services Scientific Insights Lab, Exton, PA.

Referenced from Degrazio FL. 2018, 'Holistic Considerations in Optimizing a Sterile Product Package to Ensure Container Closure Integrity', *PDA J Pharm Sci Technol.*, vol. 72, no. 1, pp. 15-34.

# Films/Coatings for Closures

- Coating: B2-Coating, Polyvinylidene fluoride (PVDF)
- Film: Fluoropolymer films (FluroTec®)



Orange color indicates FluroTec® film coverage

# Fit among the Components

- Closure Design
- **Interference Fit**
- Stack-up Tolerance
- Visual Analysis


$$\frac{\text{Stopper Plug (O.D.)} - \text{Vial Neck (I.D.)}}{\text{Stopper Plug (O.D.)}} \times 100$$

# Fit among the Components

- Closure Design
- Interference Fit
- **Stack-up Tolerance**
- Visual Analysis

$$\begin{aligned}
 & (\text{Skirt Length} - \text{Aluminum Ferrule Thickness}) \\
 & - [(\text{Vial Crown Height}) + (\text{Stopper Flange Thickness}) \times (1 - \% \text{Stopper Compression})] \\
 & = \text{Excess Skirt Length}
 \end{aligned}$$

Primary and Secondary Sealing



Sealing between the stopper and vial typically occurs in three places. The primary seal is between the flange of the stopper and the top surface of the glass, this is the land seal. The other seals are located between the plug of the stopper and the inner surface of the neck of the vials and at the transition between the plug and the flange. Image courtesy of West Pharmaceutical Services Scientific Insights Lab, Exton, PA.

# Fit among the Components

- Closure Design
- Interference Fit
- Stack-up Tolerance
- **Visual Analysis**



Acceptable




Unacceptable

On the left is a picture of an acceptable quality seal, and on the right is an unacceptable seal from a visual quality or cosmetic standpoint. Typically it is a combination of a sealing process that has been validated through the use of an appropriate CCI method and an acceptable cosmetic appearance that qualifies a package for use.

# Fit among the Components

## Typical Glass Variations



There are multiple styles of glass vial designs. These show representative styles of vials with no blowback, a North American blowback, and a European blowback. Photos courtesy of Schott AG, Mainz, Germany.

# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - Materials
  - **Measurements**
  - Environments
- Summary

当承科技(上海)有限公司文献推荐



# How to Select A Test Method?

Criteria mentioned in USP<1207.1>

- Package contents
- Package design, materials of construction, and mechanic
- Closure type and mechanics
- Maximum allowable leakage limit (MALL)
- Deterministic or probabilistic method
- Physicochemical or microbiological methods
- Method limit of detection
- Leak test detection limit
- Leak test method range
- Method outcome
- Quantitative or qualitative
- Non-destructive or destructive
- On-line or off-line

Three categories of product-package quality requirements

1

Sterility and product formulation content must be preserved.

2

Sterility, product formulation content, and gas headspace content must be preserved.


3

Sterility must be preserved: product access is required.

# Measuring Leakage – MALL

## Measuring Leakage

- Detrimental gases
- Liquid/Microorganism
- Extraneous debris



A Comparison of Leak Size Relating to Various Materials That Can Flow into or out of a Packaging System

- An array of test methods are available for proving CCI. The chart visualizes the need for more sensitive methods when preventing gas leakage versus methods that may be more appropriate for correlation with microbial ingress.

## Case-by-Case Method Development – Method Validation

Figure taken from Paskiet, D.; Asselta, R. Qualifying Integral Container Closure Systems. Presented at the PDA Annual Meeting, San Antonio, TX, 2014.

# CCI Test Method Options

Leak Method Comparison	
Deterministic methods	Probabilistic methods
Reproducible	Not reproducible
Sensitive	Insensitive
Highly instrumental	Little or no instrumentation used
Quantitative test result	Qualitative, interpretive results
Minimal sample preparation	Considerable sample preparation
Low risk of error	High risk of error
Common Examples of Analysis Techniques	
Electrical conductivity and capacitance test (HVLD)	Microbial challenge
Laser-based headspace analysis	Liquid tracer tests (e.g., dye)
Tracer gas (vacuum mode)	Bubble tests
Vacuum decay	Tracer gas (sniffer mode)
Pressure decay	-

# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - Materials
  - Measurements
  - **Environments**
- Summary

当承科技(上海)有限公司文献推荐

# Environment Considerations

## Storage Condition Varies among Drugs

- Typical recommended storage condition for drugs is at 25°C
- Most vaccines require storage and distribution at 2 – 8°C

- Many biologics must be kept frozen, whether at -20°C or -80°C
- Cell-based therapies should be shipped and distributed at cryogenic temperatures ( $\leq -150^{\circ}\text{C}$ )




**T<sub>g</sub>** of a typical rubber stopper formulation is from -50°C to -70°C

# Environment Considerations

Considerations during transportation must also be taken because temperatures can fluctuate significantly during air flight or storage under strenuous conditions such as using dry ice during shipping.

## Leakage in Cryo Packaging (X-ray Tomography at -196°C)




Under extreme environmental conditions, such as cryogenic storage, a physical shrinkage of some of the components can occur. This can be visualized through techniques such as x-ray tomography.

Referenced from Degrazio FL. 2018, 'Holistic Considerations in Optimizing a Sterile Product Package to Ensure Container Closure Integrity', *PDA J Pharm Sci Technol.*, vol. 72, no. 1, pp. 15-34.

# Content

- What is CCI?
- Importance of CCI
- Regulations and Guidances
- CCI Understanding
  - Materials
  - Measurements
  - Environments
- **Summary**

# Holistic Process to Optimize Integral Container Closure System



Referenced from Degrazio FL. 2018, 'Holistic Considerations in Optimizing a Sterile Product Package to Ensure Container Closure Integrity', *PDA J Pharm Sci Technol.*, vol. 72, no. 1, pp. 15-34.



# Thank you!



[www.westpharma.com](http://www.westpharma.com)

Visit our comprehensive **Knowledge Center** for scientific insight and more detailed technical information

West and the diamond logo and FluroTec® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. FluroTec® and B2-Coating technologies are licensed from Daikyo Seiko, Ltd.

©2020 by West Pharmaceutical Services, Inc.

All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.